Compare AbbVie Inc (ABBV) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Deutsche Bank AG — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while Deutsche Bank AG trades at $38.26 (market cap $72.15B). The key difference: AbbVie Inc is far larger — about 6.1× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.04%). Which is the better fit depends on your goals.
| ABBV | DB | |
|---|---|---|
Market Cap | $438.19B | $72.15B |
Sector | Health | Financials |
52-Week High | $263.58 | $40.33 |
52-Week Low | $197.38 | $28.37 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.91, up 1.57% on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, projected at $64.4B for 2026, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive clinical trial results for ELAHERE® and institutional buying activity underscore momentum.
The outlook remains positive given earnings beats, a 70.73% buy rating from analysts, and a $281.33 consensus price target. Key risks include patent expirations in the 2030s, high debt levels, and margin pressure. The dividend yield adds income appeal, but execution on pipeline products is critical for sustained growth.
Deutsche Bank (DB) trades at $38.06, up 1.14% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with Q2 2026 revenue growth and a 10.02 P/E ratio trading below book value at 0.79. Recent developments include being named China's renminbi clearing bank and announcing a $500 million buyback. Net income margin improved to 22.04% in 2026, though Q2 earnings missed expectations.
DB presents a mixed investment case with attractive valuation metrics and strategic positioning in European banking, but faces execution risks from recent earnings miss and ongoing tax investigations. The stock trades at a discount to peers with moderate analyst support (21% buy rating) despite strong operational cash flow of $47.06 billion in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
